• Explore /
  • Poster
  • / Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.

Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.

Abstract Poster

Authors

null

Howard Hochster

Yale University School of Medicine

Howard Hochster , Wells Messersmith , Bert O'Neil , Susan Groshen , Deirdre Cohen , Crystal Denlinger , Philip Gold , S. Eckhardt , Gershon Locker , Patricia Ames , Marti McKinley , Lawrence Leichman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

NCT01116271

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr380)

DOI

10.1200/jco.2013.31.4_suppl.380

Abstract #

380

Poster Bd #

A48

Abstract Disclosures

Similar Posters

First Author: Howard S. Hochster

First Author: Vanessa Wong

First Author: Daniel H. Ahn

First Author: Naoki Izawa